About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Long-term Observation PMS for Afatinib

NCT02131259·432 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Boehringer Ingelheim

Age

Any age

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

\- Patients with Epidermal Growth Factor Receptor (EGFR) mutation-positive inoperable or recurrent non-small cell lung cancer (NSCLC)will be included.

You may not be if

\- None

The record

StatusCompleted

PhaseNo phase

Taking part1,605

StartedMay 2014

UpdatedSep 7, 2018

Conditions

Carcinoma, Non-Small-Cell Lung

Where432

Boehringer Ingelheim Investigational Site 145
Adachi Tokyo, Japan
Boehringer Ingelheim Investigational Site 429
Aira Kagoshima, Japan
Boehringer Ingelheim Investigational Site 64
Aizuwakamatsu Fukushima, Japan

Clareo Health | Long-term Observation PMS for Afatinib